The findings of the National Institutes of Health funded study appear in the August 29 issue of PLOS ONE. Shoemaker has been studying gene therapy as a novel way to treat diseases such as botulism, a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium Clostridium botulinum.